Insulin Glulisine: Peptide Family Reference
Rapid-acting insulin analog with asparagine at B3 replaced by lysine and lysine at B29 replaced by glutamic acid for rapid absorption.
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | C257H385N65O79S6 |
| Molecular Weight | 5832.60 g/mol |
| CAS Number | 207748-29-6 |
| Product Name | Apidra |
Structure
Insulin glulisine substitutes LysB3 for AsnB3 and GluB29 for LysB29. These charge-altering modifications destabilize hexamer formation, accelerating dissociation into bioactive monomers after subcutaneous injection.
Clinical Applications
FDA-approved for type 1 and type 2 diabetes as a prandial insulin. Can be administered within 15 minutes before or 20 minutes after starting a meal.
Pharmacokinetics
- Onset: ~15 minutes
- Peak: 50-90 minutes
- Duration: 3-5 hours
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Insulin Glulisine” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Glulisine: Peptide Family Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept